glycopyrrolate has been researched along with salmeterol xinafoate in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (91.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Baldwin, M; Buckley, F; Capkun-Niggli, G; Cope, S; Donohue, JF; Ellis, A; Jansen, JP; Jones, P; Kraemer, M | 1 |
| Banerji, D; Bateman, ED; Mahler, DA; Patalano, F; Vogelmeier, CF; Wedzicha, JA | 1 |
| Asukai, Y; Costa-Scharplatz, M; Dimova, M; Keininger, D; Mezzi, K; Price, D; Ställberg, B | 1 |
| Bremner, P; Chang, CL; Day, P; Frenzel, C; Frith, PA; Kurstjens, N; Ratnavadivel, R; Thompson, PJ | 1 |
| Hubert, M | 1 |
| Cockle, SM; Huisman, EL; Ismaila, AS; Karabis, A; Punekar, YS | 1 |
| Einecke, D | 1 |
| Carrasco, J; Chehab, S; Gruenberger, JB; Keininger, DL; Molimard, M; Pitotti, C; Price, D; Reza Maleki-Yazdi, M; Sauvage, E | 1 |
| Corhay, JL | 1 |
| Darken, P; Dorinsky, P; Duncan, EA; Kerwin, E; Nyberg, J; Reisner, C; Sher, L; Siddiqui, S; Wachtel, A | 1 |
| Banerji, D; Chapman, KR; Fogel, R; Frent, SM; Gutzwiller, FS; Kostikas, K; Larbig, M; Mackay, A; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Agarwal, J; Compton, C; Czira, A; Dong, X; Duarte, M; Haeussler, K; Halpin, DMG; Ismaila, AS; Malmenäs, M; Nassim, M; Shen, Y; Tongbram, V; Vogelmeier, CF; Živković-Gojović, M | 1 |
4 review(s) available for glycopyrrolate and salmeterol xinafoate
| Article | Year |
|---|---|
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.
Topics: Albuterol; Bayes Theorem; Bronchodilator Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2013 |
Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Management; Disease Progression; Drug Combinations; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.
Topics: Bronchodilator Agents; Drug Combinations; Drug Therapy, Combination; Dyspnea; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Tiotropium Bromide; Treatment Outcome | 2015 |
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Dyspnea; Forced Expiratory Volume; Glycopyrrolate; Humans; Muscarinic Antagonists; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Tiotropium Bromide; Treatment Outcome | 2022 |
7 trial(s) available for glycopyrrolate and salmeterol xinafoate
| Article | Year |
|---|---|
Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Topics: Aged; Albuterol; Androstadienes; Bronchodilator Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Drug Costs; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Monte Carlo Method; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Sweden | 2014 |
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Australia; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Male; Middle Aged; New Zealand; Pulmonary Disease, Chronic Obstructive; Risk Factors; Salmeterol Xinafoate; Scopolamine Derivatives; Severity of Illness Index; Surveys and Questionnaires; Tiotropium Bromide; Treatment Outcome | 2015 |
[LAMA/LABA or LABA/ICS?].
Topics: Administration, Inhalation; Drug Therapy, Combination; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Indans; Lung Volume Measurements; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2015 |
[Dual bronchodilators becomes the first choice combination].
Topics: Adrenergic beta-2 Receptor Agonists; Double-Blind Method; Drug Combinations; Fluticasone; Glycopyrrolate; Guideline Adherence; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2016 |
[Study of the month : FLAME study in chronic obstructive pulmonary disease].
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Female; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Treatment Outcome | 2016 |
Efficacy, safety, and dose response of glycopyrronium administered by metered dose inhaler using co-suspension delivery technology in subjects with intermittent or mild-to-moderate persistent asthma: A randomized controlled trial.
Topics: Administration, Inhalation; Adult; Aged; Asthma; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Dry Powder Inhalers; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Salmeterol Xinafoate; Treatment Outcome; Young Adult | 2018 |
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
Topics: Bronchodilator Agents; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Salmeterol Xinafoate; Surveys and Questionnaires | 2019 |
1 other study(ies) available for glycopyrrolate and salmeterol xinafoate
| Article | Year |
|---|---|
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstruct
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Canada; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Fluticasone; France; Glycopyrrolate; Health Care Costs; Humans; Indans; Italy; Male; Portugal; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2016 |